Dr. Gralow Discusses Toxicities Experienced in the SWOG S0307 Trial

Dr. Julie Gralow Discusses the SWOG S0500 TrialПодробнее

Dr. Julie Gralow Discusses T-DM1-Induced ThrombocytopeniaПодробнее

Dr. Gralow on Future Research Into Bisphosphonates in Breast CancerПодробнее

Dr. Gralow on a Comparison of Toxicities and Patient-Stated Preference in the SWOG S0307 TrialПодробнее

Julie Gralow, MD, on the implications of the PERSEPHONE trial in early HER2+ breast cancerПодробнее

Dr. Julie R. Gralow Discusses Findings from the RxPONDER Study Released at SABCS 2020Подробнее

Dr. Gralow Gives an Analysis of the APT TrialПодробнее

Dr. Gralow on Adjuvant Bisphosphonates for Breast CancerПодробнее

Julie R. Gralow, MD: SWOG SO226 Trial and Bisphosphonates UpdateПодробнее

Thyroid Problems: Everything You Need to Know with Hashimoto's EXPERT Dr. Izabella WentzПодробнее

TOPGEAR: preoperative therapy for gastric and gastroesophageal junction adenocarcinomaПодробнее

Dr. Gralow on the Use of Bisphosphonates in Early-Stage Breast CancerПодробнее

Julie Gralow, MD, elaborates on how to differentiate CDK4/6 inhibitorsПодробнее

Jasmine’s Story – Living with CholangiocarcinomaПодробнее

Julie Gralow, MD, summarizes the RxPONDER trial from the 2020 San Antonio Breast Cancer SymposiumПодробнее

GS4-06 Estimation of breast cancer over diagnosis in a US breast screening cohortПодробнее

Julie Gralow, MD, provides details on the SWOG S0226 findings presented at SABCS 2020Подробнее

12-year follow-up of SOFT and TEXT trialsПодробнее

Julie R. Gralow, MD: New Endocrine Therapy For Metastatic Breast CancerПодробнее